Prostate Biopsy Market Key Vendors Analysis and Forecast Report 2021 February 2017

ReportsnReports.com adds new research report Global Prostate Biopsy Market 2017-2021. This
report covers the present scenario and the growth prospects of the global prostate biopsy market
for 2017-2021. To calculate the market size, the report considers the new sales of devices and
products used in prostate biopsy
Inquire for more information at
http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=917416
The following companies are the key players in the Global Prostate Biopsy Market: C.R. Bard, Cook
Medical, Endomed Systems, SOMATEX Medical Technologies, and Biomedical.
Other Prominent Vendors in the market are: Amecath, AprioMed, Argon Medical Devices,
Biopsybell, Boston Scientific, Exosome Diagnostics, MDNA Life Sciences, MDxHealth, Möller Medical,
Pathway Genomics, Predicine, Sterylab, TSK Laboratory Europe, UroMed, and Urotech.
Global Prostate Biopsy Market 2017-2021, has been prepared based on an in-depth market analysis
with inputs from industry experts. This report covers the market landscape and its growth prospects
over the coming years. The report also includes a discussion of the key vendors operating in this
market.
Purchase directly at http://www.reportsnreports.com/purchase.aspx?name=917416
One trend in the market is the new product launches and R&D activities. The vendors are
concentrating on developing technologically advanced prostate cancer testing tools especially non-
invasive methods. Most of the liquid biopsy companies are focusing on spending huge amount in
R&D activities and developing new products to enhance the diagnosis of prostate cancer. The
molecular diagnostic companies are focusing on developing advanced diagnostic tests based on
mitochondrial genome with fast DNS-sequencing machines to lead simple blood tests to cancer.
Also, diagnostic companies are collaborating with pharma company for developing non-invasive
diagnostic tests.
The study was conducted using an objective combination of primary and secondary information
including inputs from key participants in the industry. The report contains a comprehensive market
and vendor landscape in addition to a SWOT analysis of the key vendors.
Inquire for discount at http://www.reportsnreports.com/contacts/discount.aspx?name=917416
According to the report, one driver in the market is the growing incidences of prostate cancer. The
rising incidence of prostate cancer is fueling the growth of prostate biopsy market worldwide.
Prostate cancer is the second most common cancer prevalent in males after skin cancer. Prostate
cancer is found to affect men above 50 years of age and is rare in young men. According to multiple
research studies data estimates, approximately, 1.07 million to 1.17 million new prostate cancer
cases were recorded in 2012, worldwide. Another disorder associated with prostate gland is benign
prostatic hyperplasia BPH (the enlargement of the prostate). This is driving the physicians to adopt
prostate biopsies for diagnosis and screening of tumor in the prostate. For instance, according to
CDC statistics in 2013, approximately 176,450 million individuals in the US were diagnosed with
prostate cancer, while 27,681million men died from the disease.